GlassScriptPhysician profile
Amanda Walton
NPI 1407311996
$1,087.58
in general payments reported to CMS, 2019-2025
25 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $328 · 2023: $15.36 · 2024: $298 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $521.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $170.41 | 2021-2025 | Veozah |
| Channel Medsystems, INC. | $158.37 | 2022 | |
| Sumitomo Pharma America, INC. | $111.72 | 2024-2025 | Gemtesa |
| Sage Therapeutics, LLC | $76.18 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $63.77 | 2024-2025 | |
| Exeltis, USA INC. | $57.25 | 2021-2022 | |
| Boston Scientific Corporation | $38.64 | 2024 | Solyx Sis System |
| Intuitive Surgical, INC. | $37.49 | 2021 | |
| Convatec INC. | $33.50 | 2022 | |
| Abbvie INC. | $32.22 | 2021 | |
| Scynexis, INC. | $30.28 | 2022 | |
| Amgen INC. | $28.49 | 2021 | |
| Smith+Nephew, INC. | $27.35 | 2021-2022 | |
| Myovant Sciences INC. | $26.65 | 2022 | |
| Aspira Women'S Health INC | $25.71 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $23.75 | 2024 | Paragard T 380a |
| Supernus Pharmaceuticals, INC. | $19.46 | 2025 | Qelbree |
| Therapeuticsmd, INC. | $18.98 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.34 | 2024 | |
| Urovant Sciences INC | $16.74 | 2022 | |
| Coloplast Corp | $16.43 | 2021 | |
| Daiichi Sankyo INC. | $15.86 | 2021 | |
| Pfizer INC. | $15.42 | 2021 | |
| Sandoz INC. | $13.64 | 2025 | Jubbonti |
| Mylan Pharmaceuticals INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.